Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Psychotropic combination in schizophrenia.

E Acquaviva1, I Gasquet, B Falissard

  • 1INSERM U669 PSIGIAM (Paris Sud Innovation Group In Adolescent Mental health Methodology), Cochin Hospital, 97 boulevard de Port Royal, 75679 Paris cedex 14, France. EAcqua7129@aol.com

European Journal of Clinical Pharmacology
|November 12, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cannabis and mental health in adolescents: changes in associations over 15 years.

Social psychiatry and psychiatric epidemiology·2025
Same author

Influence of at-risk family interactions on the course of psychiatric care in adolescence.

European child & adolescent psychiatry·2024
Same author

Prolonged impact of the COVID-19 pandemic on self-harm hospitalizations in France: A nationwide retrospective observational study.

European psychiatry : the journal of the Association of European Psychiatrists·2022
Same author

Impact of the first wave of the COVID-19 pandemic on French Health students.

L'Encephale·2022
Same author

First use of the Adolescent Depression Rating Scale (ADRS) in the management of young people with severe acne treated with isotretinoin: a pilot study of an active monitoring of depressive disorders by dermatologists.

Clinical and experimental dermatology·2021
Same author

Medical students' learning processes the first time they role-play in psychiatry: A grounded theory study.

L'Encephale·2021
Same journal

Efficacy and safety of Ensitrelvir in COVID-19 patients: a systematic review and meta-analysis with focus on viral clearance and RNA change.

European journal of clinical pharmacology·2026
Same journal

Comparing National Health Technology Assessment approaches and the new European Joint Clinical Assessment framework: The case of onco-hematological medicines.

European journal of clinical pharmacology·2026
Same journal

The efficacy of letrozole in the medical management of ectopic pregnancy: a systematic review and meta-analysis.

European journal of clinical pharmacology·2026
Same journal

Detection of intravenous drug physicochemical incompatibilities in clinical practice: e-Harvis compared to reference tools.

European journal of clinical pharmacology·2026
Same journal

Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.

European journal of clinical pharmacology·2026
Same journal

Critical analysis of digitalis glycosides: declining use but increasing poison-center exposure cases for digitoxin.

European journal of clinical pharmacology·2026
See all related articles

This study analyzed adjunctive medications for schizophrenia, finding atypical antipsychotics are less often prescribed with antiparkinsonian drugs. Antidepressant co-prescription trends with atypical antipsychotics were observed.

Area of Science:

  • Psychiatry and Pharmacology
  • Schizophrenia Treatment Research
  • Medication Adherence Studies

Background:

  • Schizophrenia treatment frequently involves antipsychotic medications.
  • Adjunctive therapies, including antidepressants, anxiolytics, and antiparkinsonians, are common but their prescription patterns require further investigation.
  • Naturalistic studies offer valuable insights into real-world medication use, complementing randomized controlled trials.

Purpose of the Study:

  • To investigate the co-prescription patterns of adjunctive medications (antidepressants, anxiolytics, antiparkinsonians) with antipsychotic agents in schizophrenia patients.
  • To compare these co-prescription patterns across different classes of antipsychotics (typical vs. atypical).
  • To highlight the utility of naturalistic observational studies in understanding complex medication management in schizophrenia.

Related Experiment Videos

Main Methods:

  • Analysis of a national, prospective, naturalistic observational study database of prescriptions from 100 French psychiatrists in 2002.
  • Inclusion criteria: diagnosis of schizophrenia or schizoaffective disorder, age over 18.
  • Statistical analysis using log-linear and generalized linear mixed models to assess medication associations.

Main Results:

  • Over 5,000 prescriptions for 922 patients were analyzed; 32.9% received antiparkinsonian drugs.
  • Antiparkinsonian co-prescription was higher with specific antipsychotics like amisulpride, haloperidol, and depot typical antipsychotics.
  • Antidepressant and anxiolytic prescriptions were frequent (around 51-52%); atypical antipsychotics (excluding clozapine) showed a positive association with antidepressants, unlike typical antipsychotics.

Conclusions:

  • Atypical antipsychotics are less frequently associated with antiparkinsonian drugs, a trend observed with olanzapine, clozapine, and risperidone.
  • A surprising positive association trend between atypical antipsychotics and antidepressants was noted, despite some atypical agents having antidepressant properties.
  • Anxiolytic prescriptions increased across all antipsychotic types, underscoring the complexity of adjunctive medication use in schizophrenia management.